HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cis-platin in combination with low dose adriamycin and cyclophosphamide in advanced ovarian carcinoma.

Abstract
Between February 1979 and August 1981 20 patients with advanced ovarian carcinoma have been treated according to a mitigated PAC-V protocol: cis-platin 20 mg/m2 D1-5, adriamycin 35 mg/m2 D1 and cyclophosphamide 400 mg/m2 D1, and cyclophosphamide 400 mg/m2 b 7, q 28 days. Sixteen patients were evaluable with objective, measurable tumour-parameters. Minimal follow-up time was 21/2 years. Overall response rate was 50% (8/16) with complete response in 12.5% (2/16). Median duration of complete response was 40+ months, of partial response this was 16+ months. Two year survival rate was 9/16. Patients who had a complete debulking prior to PAC-V therapy or had not been treated before responded best (5/6 and 6/7 respectively). Thirteen patients indicated experiencing subjective improvement in their condition. Haematological, renal or neurological toxicity never caused threatening problems. In conclusion, a chemotherapy regimen containing a mitigated dose of adriamycin and cyclophosphamide next to full dose cis-platin yielded good tumour and patient response without severe toxicity.
AuthorsR H Verheijen, L Beex, D J Wagener, P Kenemans
JournalEuropean journal of gynaecological oncology (Eur J Gynaecol Oncol) Vol. 6 Issue 2 Pg. 116-20 ( 1985) ISSN: 0392-2936 [Print] Singapore
PMID3839751 (Publication Type: Journal Article)
Chemical References
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Cisplatin (administration & dosage, adverse effects)
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Doxorubicin (administration & dosage, adverse effects)
  • Female
  • Humans
  • Middle Aged
  • Ovarian Neoplasms (drug therapy)
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: